China Pharma Holdings (CPHI) Long-Term Deferred Tax (2011 - 2026)

China Pharma Holdings' Long-Term Deferred Tax history runs 15 years deep, the most recent figure standing at $21.8 million for Q1 2026.

• Quarterly Long-Term Deferred Tax fell 0.54% year-over-year to $21.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.8 million (down 0.54% YoY) and the FY2025 annual result came in at $21.2 million, down 2.3% from the prior year.
• Long-Term Deferred Tax was $21.8 million for Q1 2026 at China Pharma Holdings, up from $21.2 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $23.8 million in Q1 2022 and bottomed at $20.0 million in Q2 2023.
• A 5-year average of $21.8 million and a median of $21.8 million in 2026 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax plunged 43.81% — and 2023, when it advanced 7.12%.
• China Pharma Holdings' Long-Term Deferred Tax stood at $20.1 million in 2022, then advanced by 7.12% to $21.5 million in 2023, then rose by 0.78% to $21.7 million in 2024, then declined by 2.3% to $21.2 million in 2025, then rose by 2.83% to $21.8 million in 2026.
• Business Quant data shows CPHI's Long-Term Deferred Tax at $21.8 million in Q1 2026, $21.2 million in Q4 2025, and $22.7 million in Q3 2025.